行情

NVIV

NVIV

InVivo
NASDAQ

实时行情|Nasdaq Last Sale

1.520
-0.038
-2.44%
盘后: 1.530 +0.01 +0.66% 18:53 04/09 EDT
开盘
1.600
昨收
1.558
最高
1.600
最低
1.450
成交量
24.69万
成交额
--
52周最高
50.70
52周最低
1.085
市值
89.94万
市盈率(TTM)
-0.0014
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NVIV价格均价为37.50,最高价位37.50,最低价为37.50。

EPS

NVIV 新闻

更多
  • 白俄罗斯总理建议欧亚经济联盟大力推动去美元化进程
  • 央视 · 1小时前
  • 摩根大通大幅下调对美国经济前景的预期
  • 新浪财经综合 · 1小时前
  • 2.3万亿美元并非最后一搏,美联储还能继续放水!
  • 新浪财经综合 · 2小时前
  • 美股战“疫”小记:美股在这个早春都经历了什么?
  • 新浪财经综合 · 2小时前

所属板块

先进医疗设备和技术
+2.18%
医疗设备和用品
+1.91%

热门股票

代码
价格
涨跌幅

NVIV 简况

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
展开

微牛提供Invivo Therapeutics Holdings Corp(NASDAQ-NVIV)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NVIV股票新闻,以帮助您做出投资决策。